HRP20230909T1 - Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu - Google Patents
Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu Download PDFInfo
- Publication number
- HRP20230909T1 HRP20230909T1 HRP20230909TT HRP20230909T HRP20230909T1 HR P20230909 T1 HRP20230909 T1 HR P20230909T1 HR P20230909T T HRP20230909T T HR P20230909TT HR P20230909 T HRP20230909 T HR P20230909T HR P20230909 T1 HRP20230909 T1 HR P20230909T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- image
- ring
- groups
- independently
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 19
- 238000000034 method Methods 0.000 title claims 3
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 title 1
- 101100301091 Mus musculus Ralbp1 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000002619 bicyclic group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- -1 stereoisomer Chemical class 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 239000007819 coupling partner Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims 2
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 238000010976 amide bond formation reaction Methods 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (15)
1. Spoj, koji ima formulu
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
prsten B je 5-člani heteroaril;
L je C1-10 alifatična povezujuća grupa;
R1 je Ra ili Rb pri čemu je najmanje jedan R1 Rb koji je -NRdRd pri čemu dvije Rd grupe zajedno s dušikom za koji su vezane osiguravaju ne-aromatičnu C3-10 heterocikličnu grupu koja je po potrebi supstituirana s jednom ili više Re i/ili Rg grupama, u kojima je Rg halogen,
-C1-10 alifatični-C5-10 aromatični, ili =O;
svaki od R2 i R3 su nezavisno Ra;
svaki R4 i svaki R5 su nezavisno Ra ili Rb;
Ra je nezavisno pri svakom javljanju kao H, D, C1-10 alifatični, ili C1-10 cikloalifatični;
Rb je nezavisno, pri svakom javljanju za najmanje jednu od spomenutih R1, halogen ili -NRdRd pri čemu (i) svaki Rd je nezavisno Ra ili Re; ili (ii) dvije Rd grupe zajedno s dušikom za koji su vezane osiguravaju C3-10 heterocikličnu grupu;
Re je nezavisno pri svakom javljanju -ORa, -NRa, C1-6 alkil, C1-6 haloalkil, C1-6 heteroalkil, C3-6 cikloalkil, ili dvijee Re grupe koje se spajaju sa Rb grupom da bi osigurale C3-10 heterocikličnu grupu u kojoj su dve Re grupe su vezane;
m je 1 do 4;
n je 0, 1 ili 2; i
p je 0, 1, 2, 3, 4, ili 5.
2. Spoj prema zahtjevu 1, pri čemu jedinjenje ima strukturu koja zadovoljava formulu
[image]
3. Spoj prema zahtjevu 1 ili zahtjevu 2, pri čemu
(a) prsten B ima strukturu koja zadovoljava formulu
[image]
, pri čemu je najmanje jedan W azot, a svaki preostali W nezavisno je izabran između ugljika, CH, kisika, sumpora, dušika ili NH; ili
(b) prsten B je triazol izabran između
[image]
ili
(c) prsten B je oksazol izabran između
[image]
4. Spoj prema bilo kojem od zahtjeva 1-3, pri čemu je R5 Ra, pri čemu je RaC1-C4 alifatični, ili je R5 Rb, pri čemu je Rb halogen; i/ili pri čemu je R2 Ra pri čemu je Ra C1-C4 alifatični i R3 je Ra, pri čemu je Ra vodonik.
5. Spoj prema bilo kojem od zahtjeva 1-4, pri čemu je R1 Rb pri čemu je Rb -NRdRd pri čemu dvije Rd grupe zajedno s dušikom za koji su vezane osiguravaju supstituiranu, nearomatičnu C3-10 heterocikličnu grupu, čiji supstituenti sadrže najmanje dvijee Re grupe koje se spajaju da bi osigurale drugu C3-10 heterocikličnu grupu.
6. Spoj prema zahtjevu 5, pri čemu drugi C3-10 heterocikl nastao od dve Re grupe i C3-10 heterocikl nastao od dvije Rd grupe iz Rb osiguravaju spirocikličnu grupu ili bicikličnu grupu.
7. Spoj prema zahtjevu 6, pri čemu je drugi C3-10 heterocikl nastao od dvije Re grupe i C3-10 heterocikl nastao od dvije Rd grupe iz Rb osiguravaju spirocikličnu grupu i pri čemu spirociklična grupa ima bilo jednu, dvijee, tri ili četiri od karakteristike (a), (b), (c) i (d):
(a) spirociklična grupa obuhvaća najmanje dva prstena, pri čemu prvi prsten i drugi prsten spirociklične grupe imaju različit broj atoma ugljika, različit broj heteroatoma ili oba i pri čemu svaki prsten spirociklične grupe sadrži heteroatom u prstenu;
(b) spirociklična grupa obuhvaća najmanje jedan atom kisika i najmanje jedan atom dušika;
(c) spirociklična grupa obuhvaća prvi prsten spojen s atomom ugljikovog spoja, prvi prsten ima od 3 do 7 atoma i drugi prsten ima od 3 do 7 atoma; i
(d) spirociklična grupa obuhvaća više od ukupno 7atoma u spirocikličnom sistemu.
8. Spoj prema bilo kojem od zahtjeva 5-7, pri čemu je C3-10 heterocikl nastao od dve Re grupe i C3-10 heterocikl nastao od dve Rd grupe iz Rb osigurava bicikličnu grupu i biciklična grupa sadrži dva ili više heteroatoma u bicikličnoj grupi; i po potrebi pri čemu je biciklična grupa spojena biciklična grupa ili premošćena biciklična grupa i pri čemu je biciklična grupa vezana za fenil grupu prstena A Formule I preko atoma dušika biciklične grupe.
9. Spoj, koji ima formulu
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
prsten B, L, R2, R3, Re, m, n i p su kao što je definirano u zahtjevu 1;
svaki R4 i svaki R5 nezavisno su Ra ili Rb, pri čemu je Ra kao što je definirano u zahtjevu 1;
Rb je nezavisno pri svakom javljanju kao halogen ili -NRdRd pri čemu (i) svako Rd nezavisno je Ra ili Re; ili
(ii) dve Rd grupe zajedno s dušikom za koji su vezane osiguravaju C3-10 heterocikličnu grupu; i
R1 je nezavisno pri svakom javljanju
[image]
[image]
ili
[image]
pri čemu je svaki n' nezavisno cijeli broj u rasponu od 0 do 4 i R6 je nezavisno izabran između vodika, alifatičnog, aromatičnog ili heteroalifatičnog.
10. Spoj prema bilo kojem od zahtjeva 1-9, pri čemu je spoj izabran između
[image]
[image]
[image]
[image]
[image]
[image]
[image]
11. Spoj prema bilo kojem od zahteva 1-10, pri čemu je spoj
[image]
12. Farmaceutski sastav, koji sadrži; (i) spoj prema bilo kojem od zahtjeva 1-11; i (ii) ekscipijens, terapeutsko sredstvo, adjuvans ili njihove kombinacije.
13. Spoj prema bilo kojem od zahtjeva 1-11 za upotrebu kao lijek.
14. Spoj prema bilo kojem od zahtjeva 1-11, ili njegova farmaceutski prihvatljiva sol, stereoizomer, N-oksid, tautomer, hidrat, solvat, ili njegov izotop; ili farmaceutski sastav prema zahtjevu 12; za upotrebu u postupku liječenja bolesti kod subjekta koji ima, ili se sumnja da ima ili se razvija, bolest, pri čemu je bolest bolest koja uključuje kinazu protein-1 koji je u interakciji sa receptorom (RIP1) i koja je izabrana iz grupe koju čine auto-imune bolesti, inflamatorni poremećaji, kardiovaskularne bolesti, živčani poremećaji, neurodegenerativni poremećaji, alergijski poremećaji, respiratorne bolesti, bolesti bubrega, karcinomi, iskemijska stanja, deficiti eritrocita, povrede pluća i mozga, i bakterijske i virusne infekcije.
15. Postupak za stvaranje spojeva prema bilo kojem od zahtjeva 1-11, koji sadrži:
spajanje početnog materijala koji ima Formulu A s reagensom koji sadrži R1 i ima Formulu R1-H, kombiniranjem početnog materijala i reagensa koji sadrži R1 sa katalizatorom prelaznog metala, komponentom liganda, i rastvaračem kako bi nastala R1-funkcionalna grupa;
uklanjanje zaštite na amino grupi R1-funkcionalne grupe da bi se osigurao spoj amina; i
formiranje amidne veze između spoja amina i kiselog partnera za spajanje; pri čemu je Formula A
[image]
R1-funkcionalna grupa ima strukturu koja zadovoljava Formulu B
[image]
a kiseli partner za spajanje ima strukturu koja zadovoljava Formulu C
[image]
i pri čemu
X halogen ili triflat;
PG je amino zaštitna grupa;
i svaki od prstena B, L, R1, R2, R4, R5, m, n i p su kao što je navedeno u zahtevu 1;
i po potrebi pri čemu amidna veza nastaje spajanjem spoja amina i kiselog partnera za spajanje u prisustvu propilfosfonskog anhidrida i diizopropiletilamina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666452P | 2018-05-03 | 2018-05-03 | |
| EP19724662.2A EP3788045B1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
| PCT/US2019/030473 WO2019213445A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230909T1 true HRP20230909T1 (hr) | 2023-12-08 |
Family
ID=66554488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230909TT HRP20230909T1 (hr) | 2018-05-03 | 2019-05-02 | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10975064B2 (hr) |
| EP (1) | EP3788045B1 (hr) |
| JP (1) | JP7379467B2 (hr) |
| KR (1) | KR102823195B1 (hr) |
| CN (1) | CN112384510B (hr) |
| AU (1) | AU2019262142B2 (hr) |
| BR (1) | BR112020022423A2 (hr) |
| CA (1) | CA3099018A1 (hr) |
| CL (1) | CL2020002840A1 (hr) |
| CO (1) | CO2020015153A2 (hr) |
| CR (1) | CR20200582A (hr) |
| CY (1) | CY1126152T1 (hr) |
| DK (1) | DK3788045T3 (hr) |
| DO (1) | DOP2020000197A (hr) |
| EA (1) | EA202092581A1 (hr) |
| EC (1) | ECSP20077518A (hr) |
| ES (1) | ES2947446T3 (hr) |
| FI (1) | FI3788045T3 (hr) |
| HR (1) | HRP20230909T1 (hr) |
| HU (1) | HUE062277T2 (hr) |
| IL (1) | IL278416B2 (hr) |
| JO (1) | JOP20200277A1 (hr) |
| LT (1) | LT3788045T (hr) |
| MA (1) | MA52492B1 (hr) |
| MD (1) | MD3788045T2 (hr) |
| MX (1) | MX2020011622A (hr) |
| MY (1) | MY205388A (hr) |
| PE (1) | PE20210414A1 (hr) |
| PH (1) | PH12020551848A1 (hr) |
| PL (1) | PL3788045T3 (hr) |
| PT (1) | PT3788045T (hr) |
| RS (1) | RS64418B1 (hr) |
| SG (1) | SG11202010913PA (hr) |
| SI (1) | SI3788045T1 (hr) |
| SM (1) | SMT202300203T1 (hr) |
| UA (1) | UA128160C2 (hr) |
| WO (1) | WO2019213445A1 (hr) |
| ZA (1) | ZA202007487B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3788045T3 (pl) * | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| JOP20200278A1 (ar) | 2018-05-03 | 2020-11-03 | Rigel Pharmaceuticals Inc | مركبات تثبيط rip1 وطرق لتحضير واستخدامها |
| TW202122388A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Ｒｉｐ１抑制性化合物和用於製備和使用其之方法 |
| BR112022002378A2 (pt) | 2019-09-06 | 2022-06-14 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| JP2022550099A (ja) | 2019-09-27 | 2022-11-30 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| KR20250095767A (ko) * | 2019-11-07 | 2025-06-26 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
| US11690850B2 (en) * | 2019-11-26 | 2023-07-04 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| CN115867557B (zh) * | 2021-05-14 | 2025-02-18 | 中国医药研究开发中心有限公司 | 氮杂卓类稠环化合物及其医药用途 |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| US20240425524A1 (en) * | 2021-10-27 | 2024-12-26 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
| WO2023119210A1 (ko) * | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| PT96059B (pt) | 1989-12-04 | 1998-07-31 | Searle & Co | Sistema de camada unica para a administracao de um medicamento por via transdermica |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| EP3034494A1 (en) | 2007-08-15 | 2016-06-22 | President and Fellows of Harvard College | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| WO2014145022A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| US20170266199A1 (en) * | 2014-08-21 | 2017-09-21 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| MY192762A (en) | 2015-07-02 | 2022-09-07 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| EP3362449B1 (en) | 2015-10-13 | 2021-06-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| EP3366684B1 (en) | 2015-10-23 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| JOP20200278A1 (ar) | 2018-05-03 | 2020-11-03 | Rigel Pharmaceuticals Inc | مركبات تثبيط rip1 وطرق لتحضير واستخدامها |
| PL3788045T3 (pl) * | 2018-05-03 | 2023-10-09 | Rigel Pharmaceuticals, Inc. | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania |
| TW202019913A (zh) | 2018-06-26 | 2020-06-01 | 中國科學院上海有機化學研究所 | 細胞壞死抑制劑及其製備方法和用途 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| TW202122388A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Ｒｉｐ１抑制性化合物和用於製備和使用其之方法 |
| BR112022002378A2 (pt) | 2019-09-06 | 2022-06-14 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| KR20250095767A (ko) * | 2019-11-07 | 2025-06-26 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 CA CA3099018A patent/CA3099018A1/en active Pending
- 2019-05-02 UA UAA202007282A patent/UA128160C2/uk unknown
- 2019-05-02 KR KR1020207034544A patent/KR102823195B1/ko active Active
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 JO JOP/2020/0277A patent/JOP20200277A1/ar unknown
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/en active IP Right Grant
- 2019-05-02 CN CN201980045150.5A patent/CN112384510B/zh active Active
- 2019-05-02 MY MYPI2020005729A patent/MY205388A/en unknown
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 SM SM20230203T patent/SMT202300203T1/it unknown
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142B2/en active Active
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/en active Active
-
2020
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
-
2024
- 2024-02-05 US US18/432,727 patent/US20240217958A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230909T1 (hr) | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu | |
| JP6986789B2 (ja) | 化合物、その薬学的に許容される塩、化合物の使用および医薬組成物 | |
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2018528261A5 (hr) | ||
| HRP20240861T1 (hr) | Derivati 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dihlorofenil)-2-metilpirimidin-4(3h)-ona i srodni spojevi kao inhibitori ptpn11 (shp2) za liječenje raka | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| FI4083038T3 (fi) | Pyridatsinyylitiatsolikarboksiamidiyhdiste | |
| RU2018104092A (ru) | Бициклические лактамы и способы их применения | |
| HRP20120990T1 (hr) | Postupak sinteze spojeva korisnih za lijeäśenje hepatitisa c | |
| JP2021502387A5 (hr) | ||
| JP2018529650A5 (hr) | ||
| JP2018524339A5 (hr) | ||
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| JP2017505314A5 (hr) | ||
| JP2014503574A5 (hr) | ||
| JP2018536648A5 (hr) | ||
| JP2019519586A5 (hr) | ||
| HRP20220479T1 (hr) | Spojevi | |
| JP2016506959A5 (hr) | ||
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| JP2008517923A5 (hr) | ||
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| JP2006509842A5 (hr) | ||
| JP2018529737A5 (hr) |